title: Cardiovascular changes after achieving constant effect site concentration of propofol.
abstract: Target controlled infusions of propofol use a pharmacokinetic/pharmacodynamic model to calculate an effect site concentration of the drug. We assessed the cardiovascular stability of 10 healthy patients using non-invasive thoracic bioimpedance and their 'depth' of anaesthesia using the Bispectral index after they had been anaesthetised to a constant effect site concentration of propofol (6.5 min from starting). Each patient had no surgical stimulus and received no intravenous fluid during the study period. The patients also received effect site target controlled remifentanil (steady state 2.5 min from starting) and a bolus of vecuronium to facilitate intubation and ventilation. We mathematically calculated when each measured parameter would reach a state of stability (i.e. with 95% certainty). Heart rate levelled off at 20 min, Bispectral index at 32 min, and cardiac index and mean arterial pressure at 47 min after achieving effect site stability, the final levels being, respectively, 21%, 47%, 14% and 28% lower than those at effect site stability. We conclude that cardiovascular parameters continue to change to a clinically significant degree after achieving a constant effect site concentration of propofol via target controlled infusions.
authors.affiliation: Department of Anaesthesia, Stirling Royal Infirmary, Livilands, Stirling, FK8 2AU, UK. ewan.jack@nhs.net
authors.forename: E S
authors.initials: ES
authors.lastname: Jack
authors.forename: M
authors.initials: M
authors.lastname: Shaw
authors.forename: J M
authors.initials: JM
authors.lastname: Harten
authors.forename: K
authors.initials: K
authors.lastname: Anderson
authors.forename: J
authors.initials: J
authors.lastname: Kinsella
mesh_terms: D000328:Adult; D019162:Anesthetics, Combined / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D010880:Piperidines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D015742:Propofol / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000077208:Remifentanil; D013997:Time Factors
chemical_list: D019162:Anesthetics, Combined; D018686:Anesthetics, Intravenous; D010880:Piperidines; D000077208:Remifentanil; D015742:Propofol